Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 17/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 15/20 | 0.77 |
| ▸ | OPRD1 | P41143 | 15/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.48 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14635953 | 0.84 | OPRM1 (0.69) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL15156334 | 0.80 | OPRL1 (0.73) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL6498050 | 0.80 | OPRL1 (0.73) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL6363940 | 0.80 | OPRL1 (0.73) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL6775745 | 0.79 | OPRL1 (0.52) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL15155645 | 0.78 | OPRD1 (0.57) | OPRL1OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL23272067 | 0.77 | OPRL1 (0.60) | OPRL1OPRM1OPRD1OPRK1USP2 | |
| SCHEMBL5900824 | 0.77 | OPRM1 (0.75) | OPRL1OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL6780954 | 0.77 | OPRL1 (0.69) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL27979542 | 0.75 | OPRD1 (0.51) | OPRL1OPRM1OPRD1OPRK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| EP-1904451-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006136830-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ERBB2, ABL1, GRK2 | OPRL1 1161/4885OPRM1 361/4885OPRD1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.